year
vaccin
one
effect
medic
intervent
reduc
infecti
diseas
estim
save
million
live
global
year
nevertheless
mani
diseas
yet
prevent
vaccin
larg
unmet
medic
need
demand
research
develop
novel
vaccin
high
efficaci
safeti
compar
earli
centuri
vaccin
made
kill
inactiv
liveattenu
pathogen
modern
vaccin
contain
isol
highli
purifi
antigen
protein
subunit
safer
tend
induc
lower
level
protect
immun
one
strategi
overcom
latter
design
antigen
nanoparticl
assembl
polypeptid
present
multipl
copi
subunit
antigen
wellord
array
defin
orient
potenti
mimic
repetit
geometri
size
shape
natur
hostpathogen
surfac
interact
nanoparticl
offer
collect
strength
multipl
bind
site
avid
provid
improv
antigen
stabil
immunogen
sever
excit
advanc
emerg
late
includ
preclin
evid
strategi
may
applic
develop
innov
new
vaccin
exampl
protect
influenza
human
immunodefici
viru
respiratori
syncyti
viru
provid
concis
review
critic
select
data
demonstr
potenti
field
addit
highlight
use
selfassembl
protein
nanoparticl
effect
combin
emerg
disciplin
structur
vaccinolog
maximum
impact
ration
design
vaccin
antigen
vaccin
among
outstand
achiev
human
medic
histori
power
prevent
reduc
burden
infecti
diseas
make
enorm
global
impact
improv
life
qualiti
human
anim
vaccin
may
save
three
million
children
live
six
million
total
live
year
addit
contribut
increas
surviv
rate
vaccin
also
essenti
medic
tool
protect
cancer
devast
sequela
deriv
viral
bacteri
infect
human
papillomaviru
hpv
mening
allergi
autoimmun
diseas
even
drug
depend
howev
mani
import
pathogen
vaccin
yet
exist
current
vaccin
could
improv
exampl
vaccin
protect
circul
strain
pathogen
mani
microb
develop
sophist
mechan
escap
host
immun
system
mutat
antigen
microb
influenza
flu
human
immunodefici
viru
hiv
meningococcu
constitut
rapidli
chang
disguis
avoid
recognit
train
immun
cell
might
otherwis
prevent
infect
diseas
vaccin
antigen
elicit
suffici
durabl
potent
immun
addit
rise
drugresist
pathogen
entiti
caus
shigellosi
demand
attent
search
profici
vaccin
therefor
major
research
focu
seek
way
boost
vaccineinduc
host
protect
pathogen
develop
novel
antigen
evok
robust
protect
immun
respons
mani
effect
vaccin
develop
past
use
liveattenu
strain
pathogen
inactiv
kill
pathogen
liveattenu
vaccin
strain
typic
highli
immunogen
carri
inher
safeti
concern
given
potenti
weaken
viral
particl
revert
diseasecaus
virus
addit
mutagen
event
within
host
organ
may
gener
virul
strain
convers
inactiv
kill
vaccin
pathogen
replic
revert
virul
form
tend
stimul
weaker
immun
reaction
thu
may
requir
administr
multipl
dosag
import
practic
limit
effect
way
address
limit
gradual
emerg
studi
selfassembl
protein
use
nanoparticl
mediat
multicopi
antigen
display
one
earliest
exampl
selfassoci
protein
particl
report
protein
extract
tobacco
mosaic
viru
tmv
found
form
rodshap
particl
morpholog
resembl
origin
tmv
contain
genet
materi
later
hepat
b
viru
hbv
surfac
antigen
hbsag
purifi
infect
human
serum
electron
microscopi
em
ultraviolet
absorpt
studi
reveal
hbsag
form
spheric
particl
averag
diamet
nm
importantli
like
tmv
protein
particl
lack
nucleic
acid
henc
noninfecti
prepar
virusderiv
nanoparticl
form
first
efficaci
hbv
vaccin
licens
repres
mileston
creat
new
focu
field
vaccinolog
inde
antigen
nanoparticl
first
exemplifi
hbsag
emerg
lead
strategi
develop
safe
potent
vaccin
advantag
nanoparticl
antigen
key
paramet
govern
elicit
effici
immun
respons
microb
includ
antigen
densiti
distribut
pathogen
surfac
band
tcell
stimul
activ
subsequ
secret
antigenspecif
antibodi
plasma
cell
reli
effect
crosslink
bcell
surfac
immunoglobulin
bcell
receptor
bcr
recognit
pattern
present
pathogen
high
densiti
structur
order
antigen
array
present
nanoparticl
provid
molecular
scenario
multipl
bind
event
occur
simultan
nanoparticl
host
cell
bcr
fig
multival
molecular
cellular
set
favor
fruit
network
stimulatori
interact
oppos
weaker
effect
monoval
bind
afford
singl
solubl
recombin
antigen
inde
high
avid
nanoparticl
provid
multival
interact
constitut
critic
step
induct
potent
immun
reaction
fig
advantag
fig
multival
nanoparticl
favor
gener
potent
longliv
immunoprotect
germin
center
recombin
nanoparticl
load
desir
antigen
design
thoroughli
present
multipl
copi
pathogen
epitop
highli
order
manner
surfac
selfassembl
nanoparticl
oppos
singl
recombin
antigen
provid
brief
halflif
interact
bcr
polydent
natur
ie
avid
interact
nanoparticl
enabl
tighter
prolong
bind
dissoci
one
antigen
molecul
compens
bind
new
antigen
molecul
reassoci
new
bcr
b
scenario
enabl
cluster
bcr
multipl
simultan
engag
antigen
epitop
thu
bcell
trap
antigenload
nanoparticl
establish
durabl
local
strong
recognit
translat
bcell
intracellular
signal
intern
process
antigen
present
via
molecul
mhc
complex
follicular
helper
cell
tfh
within
germin
center
new
recognit
evok
secret
regulatori
cytokin
tfh
cell
ultim
evolut
b
cell
plasma
cell
secret
antigenspecif
neutral
ab
immunolog
physicochem
properti
suitabl
largescal
manufactur
via
escherichia
coli
e
coli
eukaryot
system
nanoparticl
frontlin
new
vaccin
therapeut
varieti
natur
occur
protein
selfassembl
nanoparticl
highli
symmetr
stabl
structur
organ
diamet
nm
highli
suitabl
size
rang
optim
interact
variou
cell
immun
system
nanoparticl
normal
play
divers
physiolog
role
particular
interest
context
vaccin
design
use
selfassembl
platform
display
arrang
wellord
matrix
particular
immunogen
therebi
mimick
repetit
surfac
architectur
natur
microb
eg
spheric
viru
capsid
mani
natur
protein
acquir
selfassembl
properti
evolut
de
novo
engin
protein
assembl
challeng
earli
propos
ration
perform
atom
molecular
manipul
gener
interest
new
materi
mention
richard
feynman
later
idea
combin
protein
build
block
higherord
structur
via
selfassembl
advanc
recent
feasibl
design
selfassembl
protein
improv
via
new
comput
approach
consequ
use
natur
engin
protein
nanoparticl
scaffold
vaccinologist
aim
add
heterolog
epitop
antigen
onto
plain
nanoparticl
thu
repres
limitless
sourc
possibl
chimer
nanoparticl
antigen
chimer
nanoparticl
obtain
selfassembl
coval
chemic
attach
antigen
nanoparticl
sinc
emerg
nanoparticl
vaccin
antigen
numer
attempt
gener
plain
chimer
nanoparticl
scaffold
mani
origin
describ
viruslik
particl
vlp
compos
singl
multipl
viral
antigen
case
anchor
lipid
bilay
structur
protein
differ
microorgan
serv
templat
product
nanoparticl
present
immunogen
epitop
protein
piii
filament
phage
ty
compon
saccharomyc
cerevisia
surfac
core
antigen
hepat
b
viru
surfac
coat
protein
bluetongu
viru
human
parvoviru
tobacco
mosaic
viru
picornavirida
viru
sindbi
viru
papillomaviru
exampl
minireview
focu
subset
studi
also
aim
draw
reader
attent
believ
design
futur
candid
antigen
optim
combin
structur
vaccinolog
nanoparticl
research
structur
vaccinolog
emerg
disciplin
use
insight
structur
comput
biolog
studi
neighbor
field
formul
scienc
immunolog
anim
studi
serolog
order
design
evalu
optim
deliv
lead
candid
vaccin
antigen
minor
note
synthet
nanoparticl
made
nonpolypeptid
polym
metal
solid
support
use
encapsul
particl
vaccin
deliveri
system
beyond
scope
current
review
reader
direct
altern
sourc
mani
virus
encod
protein
form
stabl
nanoparticl
structur
selfassembl
infect
host
cell
order
packag
viral
genom
prerequisit
propag
howev
scaffold
protein
assembl
absenc
genet
materi
noninfecti
nonrepl
viruslik
particl
vlp
close
resembl
intact
virion
obtain
consequ
viral
nanoparticl
vlp
compos
one
recombin
selfassembl
protein
among
first
antigennanoparticl
candid
inde
develop
success
market
vaccin
inde
earliest
vlp
rel
simpli
obtain
selfassembl
singl
recombin
hbv
hpv
capsid
protein
excel
result
obtain
first
plain
vlp
sever
chimer
vlp
explor
platform
display
heterolog
epitop
antigen
notabl
exampl
categori
discuss
also
briefli
discuss
complex
vlp
repres
envelop
virus
contrast
vlp
made
highli
purifi
protein
capsid
envelop
vlp
virosom
assembl
bud
host
cell
membran
extens
review
viral
vlp
vaccin
focu
challeng
industri
develop
manufactur
found
elsewher
second
half
centuri
first
genet
engin
vaccin
develop
clone
vp
capsid
protein
footandmouth
diseas
viru
fmdv
demonstr
safe
stabl
effect
polypeptid
vaccin
cattl
swine
breakthrough
genet
fmdv
anim
vaccin
coupl
discoveri
hbsag
vaccin
antigen
purifi
human
serum
stimul
search
safe
genet
vitroproduc
vaccin
protect
human
hbv
licensur
obtain
first
human
vaccin
base
recombin
protein
subunit
antigen
hbsag
selfassembl
nanoparticl
although
assembl
form
nanoparticl
close
resembl
intact
hbv
virion
thu
fulli
consid
vlp
nevertheless
recombin
hbsag
nanoparticl
includ
two
safe
efficaci
vaccin
market
engerixb
recombivaxhb
global
implement
protect
hbv
perhap
first
real
vlp
human
vaccin
success
stori
two
similar
vaccin
protect
hpv
infect
major
caus
anogenit
diseas
especi
cervic
cancer
vaccin
launch
first
decad
centuri
market
cervarix
gardasil
contain
recombin
hpv
major
capsid
protein
vlp
develop
vaccin
follow
work
first
report
emerg
describ
selfassembl
recombin
form
major
capsid
protein
sever
virus
includ
hepat
b
polyoma
parvoviru
studi
earli
reveal
recombin
bovin
human
papillomavirus
could
selfassembl
empti
capsidlik
nanoparticl
nm
diamet
importantli
nanoparticl
could
rais
hightit
neutral
antibodi
anim
immunogen
profil
similar
infecti
hpv
virion
notabl
denatur
nonassembl
form
induc
neutral
antibodi
highlight
import
correct
nanoparticul
structur
protect
epitop
vlp
sever
highresolut
crystal
structur
differ
hpv
protein
determin
reveal
molecular
basi
oligomer
pentamer
assembl
unit
viral
shell
cryoem
studi
enabl
reconstruct
entir
hpv
type
capsid
alon
bound
neutral
fab
fragment
togeth
structur
studi
provid
deep
understand
hpv
structur
antigen
specif
assembl
nanoparticl
vlp
deriv
hpv
type
bival
cervarix
addit
type
first
quadrival
gardasil
nonaval
gardasil
form
basi
safe
highli
efficaci
vaccin
tabl
hpv
vaccin
current
rel
high
product
cost
strain
coverag
efficaci
specif
type
includ
formul
thu
leav
room
improv
potenti
secondgener
vaccin
nevertheless
hpv
vlp
repres
shine
exampl
encourag
develop
implement
addit
nanoparticl
vaccin
addit
research
clinic
develop
hpv
nanoparticl
vaccin
numer
virus
exampl
rotaviru
polioviru
herpesviru
parvoviru
use
gener
noninfecti
vlp
vaccin
candid
although
current
mostli
without
success
clinic
develop
howev
increas
understand
selfassembl
nanoparticl
vlp
product
technolog
led
new
opportun
make
chimer
vlp
display
heterolog
epitop
antigen
attach
vlp
either
coval
modif
chemic
crosslink
genet
engin
discuss
first
viral
nanoparticl
discov
effici
produc
recombinantli
character
hbv
compos
either
surfac
antigen
hbsag
describ
core
antigen
hbcag
hbcag
first
shown
selfassembl
particl
nm
diamet
resembl
viral
core
obtain
hbvinfect
human
liver
highli
immunogen
anim
later
cryoem
studi
reveal
hbcag
produc
e
coli
selfassembl
two
class
differ
size
nanoparticl
diamet
correspond
protom
landmark
studi
brown
cowork
show
chimer
recombin
form
hbcag
genet
fuse
foreign
fmdv
peptid
epitop
could
produc
viral
express
system
selfassembl
nanoparticl
display
fmdv
epitop
chimera
significantli
potent
free
fmdv
peptid
peptid
coupl
betagalactosidas
carrier
protein
highli
potent
rais
neutral
antibodi
fmdv
hbv
mani
analog
studi
subsequ
perform
exampl
show
human
rhinoviru
peptid
present
hbcag
particl
immunogen
uncoupl
peptid
overal
mani
studi
reveal
number
site
hbv
nanoparticl
suitabl
insert
display
foreign
epitop
order
ensur
optim
present
immun
system
also
emerg
carrierspecif
immunosuppress
preexist
immun
hbcag
significantli
alter
immunogen
chimer
particl
thu
potenti
allow
repeat
immun
nanoparticl
platform
collect
find
support
use
hbcag
nanoparticl
similar
vlp
effici
scaffold
present
heterolog
foreign
epitop
vaccin
antigen
inde
long
search
vaccin
malaria
success
clinic
trial
perform
use
chimer
nanoparticl
antigen
contain
epitop
circumsporozoit
protein
csp
plasmodium
falciparum
p
falciparum
malaria
parasit
genet
fuse
either
hbcag
malarivax
hbsag
mosquirix
latter
construct
present
csp
residu
p
falciparum
key
compon
rt
mosquirix
vaccin
european
medicin
agenc
express
posit
scientif
opinion
follow
largescal
safeti
efficaci
data
phase
iii
clinic
trial
tabl
although
latter
probabl
notabl
clinic
advanc
new
applic
literatur
contain
mani
exampl
nanoparticl
vlp
use
carrier
epitop
enter
clinic
trial
exampl
vaccin
present
hundr
copi
nicotin
hapten
coval
attach
selfassembl
nanoparticl
made
bacteriophag
coat
protein
shown
safe
abl
gener
antibodi
respons
potenti
benefici
smoke
cessat
similarli
enter
clinic
trial
platform
peptid
repres
epitop
conjug
display
immunotherapi
alzheim
diseas
interestingli
hbcag
recent
use
success
preclin
studi
nanoparticl
scaffold
present
structur
optim
antigen
respiratori
syncyti
viru
rsv
lead
caus
sever
respiratori
tract
diseas
children
worldwid
mani
previou
effort
design
vaccin
antigen
protect
rsv
focus
surfaceexpos
fusion
glycoprotein
f
highli
conserv
target
neutral
antibodi
schief
cowork
perform
pioneer
studi
use
insight
crystal
structur
neutral
epitop
f
antigen
order
comput
design
optim
stabil
conform
conjug
present
hbcag
nanoparticl
antigen
alon
moder
immunogen
show
much
higher
abil
induc
protect
rsvneutral
antibodi
sever
anim
model
includ
rhesu
macaqu
present
multipl
copi
hbcag
scaffold
formul
design
rsv
f
epitop
chemic
conjug
form
hbcag
produc
e
coli
expos
reactiv
ly
genet
engin
major
immunodomin
region
hbcag
bipartit
approach
separ
produc
purifi
optim
antigen
carrier
compon
follow
conjug
avoid
potenti
size
limit
antigen
incorpor
nanoparticl
via
genet
fusion
although
product
process
thu
rather
complic
neutral
activ
elicit
compar
titer
induc
natur
human
infect
suggest
proof
principl
epitopefocus
structurebas
antigen
design
combin
selfassembl
nanoparticl
display
hold
great
promis
futur
vaccin
fig
hepat
e
viru
hev
constitut
anoth
success
exampl
gener
recombin
vlp
efficaci
prevent
progress
infect
insect
cell
use
prepar
hev
particl
truncat
version
hev
viral
capsid
protein
yield
antigen
similar
origin
hev
viral
particl
bacteriaderiv
hev
particl
shorter
polypeptid
subunit
render
efficaci
current
phase
iv
clinic
trial
hecolin
need
nextgener
vaccin
influenza
one
biggest
driver
research
novel
vlp
antigen
sever
decad
influenza
vaccin
success
produc
use
embryon
chicken
egg
nevertheless
consider
effort
invest
devis
altern
product
method
recombin
influenza
antigen
might
increas
vaccin
manufactur
speed
yield
volum
puriti
safeti
overcom
potenti
inabl
provid
suffici
vaccin
dose
event
futur
widespread
epidem
pandem
particular
sever
group
explor
influenza
viruslik
particl
vlp
selfassembl
hemagglutinin
ha
neuraminidas
na
antigen
lipid
bilay
support
matrix
protein
gener
noninfecti
particl
approxim
nm
diamet
thu
resembl
influenza
virion
follow
progress
make
recombin
selfassembl
vlp
insect
cell
influenza
vlp
shown
promis
immunogen
recombin
system
enabl
tailor
antigen
express
level
overcom
issu
low
abund
na
tradit
eggbas
influenza
vaccin
use
system
recombin
vlp
design
protect
avian
influenza
strain
gener
latter
induc
protect
immun
ferret
show
posit
phase
clinic
result
moreov
sever
similar
vlp
vaccin
test
preclin
studi
exampl
vlp
produc
mammalian
cell
rais
high
titer
neutral
antibodi
mice
mice
broadli
protect
vaccin
cocktail
vlp
display
hemagglutinin
antigen
data
suggest
influenza
vlp
approach
may
applic
rapid
respons
potenti
pandem
strain
moreov
also
use
prepar
season
quadrival
influenza
vaccin
qiv
clinic
trial
ongo
nevertheless
novel
approach
prevent
influenza
individu
age
older
achiev
develop
flublok
first
recombin
influenza
vaccin
licens
trival
vaccin
contain
recombin
ha
protein
three
strain
season
influenza
viru
higher
antigen
load
report
improv
immunogen
efficaci
produc
insect
cell
protein
adopt
multimer
nanoparticul
structur
nm
diamet
character
dynam
light
scatter
electron
microscopi
influenza
one
promis
target
recombin
vlp
technolog
viral
target
prove
challeng
especi
sever
viral
protein
requir
vlp
assembl
although
current
licens
rotaviru
rv
vaccin
efficaci
improv
rv
vaccin
need
provid
greater
protect
develop
countri
improv
protect
mild
gastroenter
end
sever
rotaviru
vlp
test
preclin
model
exampl
doublelay
rv
vlp
nm
diamet
obtain
use
insect
cell
express
made
recombin
protein
abund
rv
antigen
confer
partial
protect
anim
requir
adjuv
prime
liveattenu
rv
vaccin
recent
progress
made
use
e
coli
suitabl
lowcost
scalabl
product
system
rotaviru
vlp
elicit
strong
antibodi
respons
protect
rvinduc
diarrhea
mice
rv
studi
suggest
vlp
hold
promis
like
requir
addit
optim
composit
immun
rout
effect
adjuv
efficaci
human
attempt
make
hiv
vaccin
also
includ
variou
differ
vlp
mostli
involv
lipidenvelop
assembl
intern
hiv
gag
provid
support
exposur
trimer
env
crucial
hiv
target
antigen
neutral
antibodi
number
preclin
studi
shown
potenti
approach
effici
induc
humor
cellular
immun
respons
initi
futur
human
clinic
trial
use
emerg
hiv
vlp
vaccin
candid
facilit
clinic
develop
experi
manufactur
safeti
etc
accru
gener
influenza
rotaviru
vaccin
describ
human
noroviru
nov
caus
endem
viral
diarrheal
diseas
may
caus
half
gastroenter
outbreak
worldwid
therefor
gain
increas
attent
anoth
pathogen
caus
global
signific
healthcar
burden
candid
nov
vlp
vaccin
develop
use
recombin
protein
major
nov
antigen
selfassembl
nanoparticl
diamet
nm
close
resembl
nativ
virion
number
clinic
trial
perform
tabl
show
nov
vlp
vaccin
well
toler
induc
rapid
robust
immun
respons
adult
howev
clinic
trial
report
date
result
demonstr
modest
protect
infect
diseas
prevent
sever
gastroenter
healthi
subject
efficaci
data
key
risk
group
yet
emerg
vlp
platform
appear
promis
key
question
nov
vaccin
develop
breadth
protect
multipl
variant
genotyp
strain
potenti
resolv
use
multival
nov
vlp
cocktail
viral
exampl
describ
clearli
demonstr
success
futur
promis
use
highli
purifi
nonenvelop
viral
capsid
protein
plain
chimer
antigen
nanoparticl
howev
envelop
vlp
due
inclus
lipid
bilay
addit
structur
protein
antigen
repres
complex
challeng
partli
overcom
via
breakthrough
mammalian
insect
cell
express
technolog
unlik
simpler
nonenvelop
viral
protein
nanoparticl
envelop
vlp
inher
safeti
issu
due
potenti
contamin
express
system
use
may
challeng
formul
longterm
stabil
profil
nevertheless
sever
envelop
vlp
candid
clinic
trial
addit
viral
nanoparticl
vlp
mani
natur
occur
selfassembl
protein
nanoparticl
identifi
wide
varieti
sourc
exampl
almost
live
organ
produc
ferritin
protein
whose
main
function
intracellular
iron
storag
ferritin
made
subunit
compos
fouralphahelix
bundl
selfassembl
quaternari
structur
octahedr
symmetri
fig
sever
highresolut
structur
ferritin
determin
confirm
helicobact
pylori
ferritin
made
ident
protom
wherea
anim
ferritin
light
heavi
chain
assembl
alon
combin
differ
ratio
particl
subunit
ferritin
selfassembl
nanoparticl
robust
thermal
chemic
stabil
henc
ferritin
nanoparticl
potenti
wellsuit
carri
expos
immunogen
moreov
sinc
ferritin
compos
eight
unit
threefold
axi
symmetri
conveni
scaffold
present
trimer
antigen
inde
nabel
cowork
report
eleg
structurebas
design
strategi
gener
ferritin
nanoparticl
genet
engin
present
multival
array
flu
viru
hemagglutinin
ha
nativ
trimer
conform
intact
ha
key
antigen
compon
flu
vaccin
immun
mice
haferritin
nanoparticl
yield
promis
outcom
compar
current
commerci
vaccin
anim
respond
potent
immun
respons
illustr
notabl
higher
number
neutral
antibodi
enhanc
breadth
coverag
unmatch
virus
increas
gener
neutral
ab
two
highli
conserv
yet
independ
flu
epitop
work
one
first
clear
exampl
structur
optim
present
order
array
wellfold
immunogen
induc
stronger
protect
recent
work
aim
toward
univers
flu
vaccin
provid
broad
coverag
protect
differ
subtyp
flu
viru
yassin
et
al
report
refin
structurebas
gener
ferritinbas
nanoparticl
display
fig
gener
chimer
nanoparticl
surfaceexpos
array
immunogen
epitop
recombin
dna
technolog
use
make
gene
encod
selfassembl
polypeptid
fuse
desir
immunogen
epitop
subsequ
product
chosen
cell
express
system
chimer
polypeptid
selfassembl
within
cell
order
pattern
surfac
expos
epitop
depict
model
ferritin
shown
grey
isosurfac
pdb
selfassembl
eight
ident
unit
compos
trimer
ferritin
left
panel
one
trimer
visual
within
one
nanoparticl
unit
monom
color
orang
green
cyan
given
intrins
propens
ferritin
selfassembl
highli
symmetr
order
quaternari
architectur
chimer
nanoparticl
gener
ha
epitop
shown
right
panel
orang
green
cyan
cartoontub
format
pdb
incorpor
project
matrix
order
surfac
expos
epitop
readi
recognit
bcr
describ
recent
figur
prepar
use
pymol
softwar
pymol
molecular
graphic
system
version
llc
stem
region
ha
glycoprotein
yet
capabl
evok
broadli
crossreact
antibodi
contrast
plain
nanoparticl
protect
mice
ferret
lethal
dose
heterosubtyp
viru
anoth
similar
studi
also
report
nabel
team
wherein
conserv
receptorbind
domain
site
vulner
antigen
epsteinbarr
viru
present
structur
optim
orient
nanoparticl
ferritin
subunit
encapsulin
subunit
preclin
studi
chimer
antigen
elicit
potent
virusneutr
antibodi
titer
solubl
antigen
alon
importantli
addit
immunofocus
abil
gener
highqual
antibodi
respons
recombin
natur
nanoparticl
antigen
benefit
high
puriti
safeti
toler
strengthen
appropri
vaccin
strategi
tabl
also
recent
work
et
al
describ
silico
studi
optim
molecular
scaffold
epitop
present
lead
gener
recombin
ferritin
nanoparticl
display
epitopescaffold
harbor
epitop
hepat
c
viru
promis
candid
preclin
studi
quest
hcv
vaccin
recent
exampl
appli
hcv
build
epitopescaffold
ration
design
strategi
emerg
previou
attempt
graft
hiv
epitop
onto
heterolog
protein
scaffold
effect
combin
approach
multival
nanoparticl
format
ferritin
also
use
antigen
support
search
potent
safe
vaccin
tool
hiv
despit
identif
year
ago
remain
one
devast
pathogen
afflict
human
popul
order
circumv
fact
ab
other
socal
broadli
neutral
antibodi
bnab
might
occlud
highli
vulner
hiv
site
kwong
cowork
graft
seri
hiv
target
motif
differ
protein
templat
result
chimera
name
supersit
transplant
transplant
bear
glycopeptid
variabl
region
recogn
neutral
antibodi
three
differ
donor
bind
enhanc
present
transplant
ferritin
nanoparticl
lumazin
synthas
ls
repres
anoth
exampl
inclus
bacteri
particul
base
optim
vaccin
candid
report
recent
jardin
et
al
attempt
enhanc
immunoreact
recombin
hiv
infect
mention
hiv
repres
major
health
problem
worldwid
million
peopl
carri
viru
worldwid
yearli
morbid
million
peopl
avert
http
wwwavertorgworldwidehivaidsstatisticshtm
lack
vaccin
enorm
unmet
medic
need
key
challeng
design
antihiv
vaccin
high
mutagen
capabl
viru
unfeas
administ
attenu
kill
viru
safeti
issu
addit
hurdl
neglig
recognit
potenti
germlin
precursor
bnab
wildtyp
major
immunogen
compon
hiv
viru
envelop
one
way
overcom
obstacl
recent
report
schief
cowork
boost
affin
germlin
antibodi
viral
glycoprotein
display
multipl
copi
engin
form
antigen
lumazin
synthas
ls
nanoparticl
ls
respons
penultim
catalyt
step
biosynthesi
riboflavin
enzym
present
broad
varieti
organ
includ
archaea
bacteria
fungi
plant
eubacteria
ls
monom
amino
acid
long
consist
betasheet
along
tandem
alphahelic
flank
side
number
differ
quaternari
structur
report
ls
illustr
morpholog
versatil
homopentam
symmetr
assembl
pentam
form
capsid
diamet
even
ls
cage
subunit
describ
use
ls
thermophil
bacterium
aquifex
aeolicu
nanoparticl
platform
epitop
display
jardin
et
al
succeed
increas
potenc
immun
respons
breadth
coverag
hiv
envelop
env
glycoprotein
hiv
surfac
protein
target
neutral
antibodi
made
three
precursor
trimer
cleav
subunit
jardin
et
al
engin
ls
display
optim
subcompon
term
wildtyp
antigen
env
trimer
approach
overcam
issu
germlin
precursor
bnab
show
undetect
affin
wildtyp
env
addit
structur
stabil
trimer
provid
ntermin
coiledcoil
domain
immunogen
fuse
cterminu
ls
gene
construct
result
recombin
nanoparticl
antigen
effici
obtain
mammalian
cell
stabl
homogen
selfassembl
ls
monom
present
glycosyl
contrast
monomer
stimul
bcell
activ
nanoparticl
remark
activ
germlin
matur
b
cell
accord
relat
studi
discuss
jardin
et
al
also
hypothes
abil
nanoparticl
induc
crosslink
bcell
receptor
import
promot
success
immun
respons
method
obtain
protein
micel
fulllength
amphiphil
membran
protein
develop
use
prepar
viral
surfac
protein
watersolubl
particl
hydrophob
interior
polar
exterior
rel
homogen
size
approxim
nm
diamet
depend
protein
therein
simon
et
al
predict
sever
possibl
applic
approach
includ
opportun
make
viru
glycoprotein
micel
vaccin
inde
similar
approach
adapt
prepar
protein
nanoparticl
compris
amphiphil
antigen
protein
micel
prepar
extract
nonion
deterg
insect
cell
express
recombin
antigen
compel
exampl
slightli
genet
modifi
fulllength
form
rsv
fusion
f
surfac
glycoprotein
extract
purifi
insect
cell
membran
use
creat
protein
nanoparticl
micel
nm
diamet
trimer
f
protein
assembl
rosett
expos
conform
epitop
similar
postfus
f
conform
abl
rais
neutral
ab
recent
clinic
trial
rsv
f
antigen
nanoparticl
appear
safe
promot
immunogen
reduc
rsv
infect
rais
high
expect
nanoparticl
vaccin
rsv
micellar
nanoparticl
approach
also
exploit
search
vaccin
coronavirida
viru
cov
famili
repres
import
group
emerg
human
pathogen
wit
sever
acut
respiratori
syndrom
sarscov
middl
east
respiratori
syndrom
merscov
outbreak
respect
recombin
fulllength
form
major
immunodomin
cov
antigenth
amphiphil
spike
glycoproteinsboth
sarscov
merscov
success
obtain
via
nonion
detergentextract
cell
purifi
spike
protein
assembl
nanoparticl
nm
diamet
adjuv
formul
test
mice
capabl
rais
hightit
neutral
antibodi
respons
homolog
viru
preclin
exampl
suggest
protein
nanoparticl
approach
may
suitabl
rapid
product
rel
simpl
effect
vaccin
respons
emerg
pathogen
tabl
propos
perform
molecular
manipul
exploit
chemic
forc
repetiti
fashion
could
lead
product
interest
materi
date
back
least
inde
addit
natur
occur
selfassembl
protein
describ
sever
group
explor
way
design
produc
nanoparticl
materi
base
nonn
polypeptid
exampl
burkhard
cowork
produc
chimer
polypeptid
capabl
selfassembl
regular
polyhedr
nanoparticl
polypeptid
consist
ntermin
pentamerform
subunit
deriv
cartilag
oligomer
matrix
protein
comp
follow
de
novodesign
trimer
subunit
domain
subunit
present
oligomer
coiledcoil
conform
importantli
result
synthet
molecul
shown
refold
selfassembl
nanoparticl
polyhedr
symmetri
altern
oligomer
motif
trimer
foldon
domain
fibritin
also
use
design
assembl
nanoparticl
give
rise
multival
molecular
architectur
allow
divers
immunogen
epitop
repeatedli
display
surfac
nanoparticl
strictli
arrang
manner
strategi
appear
broadli
applic
inde
use
polypeptid
approach
burkhard
team
fuse
ctermin
heptad
repeat
hrc
region
sarscov
spike
protein
prefusogen
state
frame
nanoparticl
scaffold
strategi
allow
conserv
trimer
coiledcoil
conform
spike
epitop
immun
mice
sarsnanoparticl
success
elicit
neutral
antibodi
specif
trimer
coiledcoil
epitop
prefusogen
hrc
addit
applic
system
target
hiv
vaccin
use
nanoparticl
made
two
coval
link
coiledcoil
domain
design
incorpor
membran
proxim
extern
region
mper
howev
high
mperspecif
titer
rais
nanoparticl
none
sera
display
detect
neutral
activ
promisingli
similarli
design
polypeptid
nanoparticl
display
multipl
copi
rodent
malaria
epitop
circumsporozoit
protein
plasmodium
berghei
elicit
longlast
immun
respons
collect
preclin
research
suggest
selfassembl
protein
nanoparticl
sapn
approach
gener
safe
nonn
polypeptid
antigen
approxim
size
multival
scenario
viru
thu
facilit
recognit
antigen
immun
receptor
earli
centuri
yeat
cowork
develop
nanohedra
proteindesign
method
subsequ
extend
nobl
cowork
yeat
team
ration
design
genet
fusion
trimer
bromoperoxidas
dimer
matrix
protein
influenza
viru
combin
two
natur
oligomer
protein
gener
selfassembl
nanostructur
includ
molecular
cage
filament
superstructur
later
wellord
tetrahedr
cage
subunit
design
crystal
structur
determin
reveal
close
match
intend
design
valid
approach
nobl
team
use
protein
higher
symmetri
allow
design
fusion
two
connect
gener
regular
molecular
array
form
protein
lattic
close
nanohedr
particl
sever
subsequ
silico
crystallograph
studi
develop
nanostructur
design
strategi
includ
gener
particl
nm
diamet
therefor
develop
power
comput
approach
ab
initio
design
new
proteinprotein
interfac
defin
symmetri
geometri
complementari
pack
arrang
increas
number
protein
structur
pdb
specul
addit
achiev
field
selfassembl
protein
design
possibl
interest
see
scaffold
fulli
exploit
display
antigen
epitop
suitabl
full
develop
clinic
efficaci
vaccin
despit
mani
success
field
vaccinolog
new
breakthrough
still
need
protect
human
sever
import
lifethreaten
diseas
review
varieti
noninfecti
biolog
nanoparticl
offer
solut
exampl
plain
nanoparticl
eg
hbsag
hpv
protein
simpl
molecular
selfassembl
safe
efficaci
vaccin
antigen
licens
human
use
complex
chimer
nanoparticl
platform
pathogenderiv
immunogen
motif
present
host
immun
system
biolog
scaffold
rang
synthet
polypeptid
nativ
macromolecul
ferritin
lumazin
synthas
vlpform
antigen
lipidenvelop
vlp
chimer
nanoparticl
evid
immunogen
platform
carrier
neglig
low
compar
mount
immunogen
present
nanoparticl
display
order
matrix
immunogen
enabl
fruit
engag
bcell
receptor
singl
recombin
immunogen
establish
sever
anim
model
clinic
studi
report
exemplifi
high
effici
nanostructur
elicit
potent
longlast
immun
follow
success
clinic
studi
recombin
nanoparticlebas
vaccin
malaria
emerg
two
vaccin
alreadi
avail
prevent
hpvrelat
diseas
recent
preclin
studi
demonstr
comput
structur
biolog
combin
ration
design
wellori
array
protect
epitop
pathogen
manner
suitabl
rais
desir
immun
respons
comput
ab
initio
design
selfassembl
molecul
becom
ever
possibl
thu
enrich
molecular
repertoir
nanoparticl
scaffold
consequ
design
plain
chimer
nanoparticl
antigen
abil
manufactur
recombinantli
prokaryot
eukaryot
system
make
safe
effect
immunogen
becom
realiti
shown
vaccin
clinic
trial
broad
rang
diseas
ongo
establish
exampl
success
vaccin
diseas
viral
parasit
origin
hepat
b
hpv
malaria
next
decad
may
consolid
use
multival
nanoparticl
therapeut
tool
futur
infecti
diseas
origin
bacteri
fungal
also
cancer
disord
hypertens
asthma
addict
eg
smoke
amazingli
versatil
tool
may
also
get
us
closer
univers
vaccin
highli
variabl
pathogen
hiv
influenza
mening
continu
effort
still
need
wellfound
optim
studi
nanoparticl
vlp
togeth
implement
structur
vaccinolog
facilit
emerg
bcell
clone
antibodi
product
technolog
translat
new
secondgener
vaccin
contribut
save
live
worldwid
author
employe
glaxosmithklin
vaccin
srl
via
fiorentina
siena
itali
